Literature DB >> 17465231

Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine model.

A Caporale1, A Brescia, G Galati, M Castelli, S Saputo, I Terrenato, A Cucina, A Liverani, M Gasparrini, A Ciardi, M Scarpini, U M Cosenza.   

Abstract

BACKGROUND: Local therapy with IL-2 may be very effective in the treatment of different forms of cancer. The aim of this study was to determine the effectiveness of IL-2 locoregional application in the treatment of colon cancer.
MATERIALS AND METHODS: Twenty eight syngenic BDIX rats were utilized in this study. The rats were divided into two groups of fourteen animals: group T (treatment) and group C (control). All rats of both groups were injected, under the splenic capsule, with T 10(7) DHD/K2/ TRb neoplastic cells. Then, within and around the site of the previous inoculation, the T group was injected with 1 ml of glucosate solutions + 0.1% albumin (BSA) containing 2.5 x 10(6) IU of IL-2 ( Proleukin-Chiron), whereas the C group was injected with 1 ml of BSA alone. After three weeks, rats were sacrificed and the liver and spleen were removed. The following parameters were considered: volume and weight, neoplastic-non neoplastic tissue index of the spleen, mitotic index and vascular density of splenic and hepatic lesions.
RESULTS: All the studied parameters showed statistically significant differences in treated and untreated animals.
CONCLUSION: This study of a murine model demonstrated that IL-2 locoregional therapy may be effective in the treatment of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465231

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.

Authors:  A Strillacci; C Griffoni; G Lazzarini; M C Valerii; S Di Molfetta; F Rizzello; M Campieri; M P Moyer; V Tomasi; E Spisni
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

2.  Anti-colorectal cancer effect of interleukin-2 and interferon-β fusion gene driven by carcinoembryonic antigen promoter.

Authors:  Yan Wang; Mengchun Wang; Yan Li
Journal:  Onco Targets Ther       Date:  2016-05-30       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.